Clinical Trial Update: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study results assess the clinical and immunologic effects of ALT-803 in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ALT-803 (Interleukin-15 super-agonist)

Snippet

Sponsor: Altor BioScience | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2025-01-22